MERIAN GLOBAL INVESTORS UK Ltd lowered its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 59.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 319,444 shares of the biotechnology company’s stock after selling 471,015 shares during the quarter. MERIAN GLOBAL INVESTORS UK Ltd owned approximately 0.73% of United Therapeutics worth $40,850,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of the business. Legacy Financial Advisors Inc. purchased a new position in United Therapeutics during the second quarter worth approximately $107,000. Sun Life Financial INC purchased a new position in United Therapeutics during the second quarter worth approximately $198,000. Fox Run Management L.L.C. purchased a new position in United Therapeutics during the second quarter worth approximately $269,000. HL Financial Services LLC lifted its position in United Therapeutics by 32.1% during the second quarter. HL Financial Services LLC now owns 2,711 shares of the biotechnology company’s stock worth $307,000 after buying an additional 658 shares in the last quarter. Finally, Worldquant Millennium Quantitative Strategies LLC purchased a new position in United Therapeutics during the second quarter worth approximately $347,000. Institutional investors own 95.71% of the company’s stock.
In other United Therapeutics news, Director Christopher Causey sold 810 shares of the firm’s stock in a transaction on Monday, September 10th. The stock was sold at an average price of $119.00, for a total transaction of $96,390.00. Following the completion of the sale, the director now owns 1,555 shares of the company’s stock, valued at $185,045. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Richard Giltner sold 3,240 shares of the firm’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $129.38, for a total value of $419,191.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,860 shares of company stock valued at $611,161. 8.20% of the stock is owned by insiders.
United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.23 by ($0.81). The business had revenue of $412.70 million for the quarter, compared to analyst estimates of $378.22 million. United Therapeutics had a return on equity of 25.24% and a net margin of 31.73%. United Therapeutics’s revenue was down 7.4% compared to the same quarter last year. During the same period last year, the business earned $4.69 EPS. As a group, sell-side analysts anticipate that United Therapeutics Co. will post 14.39 EPS for the current year.
A number of brokerages recently commented on UTHR. JPMorgan Chase & Co. lifted their price objective on United Therapeutics from $118.00 to $126.00 and gave the stock a “neutral” rating in a research report on Friday, November 2nd. Credit Suisse Group reduced their price objective on United Therapeutics from $106.00 to $103.00 and set an “underperform” rating on the stock in a research report on Thursday, November 1st. HC Wainwright reiterated a “hold” rating and set a $95.00 price objective on shares of United Therapeutics in a research report on Thursday, November 1st. Cowen set a $106.00 price objective on United Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, October 31st. Finally, Zacks Investment Research downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 22nd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $136.25.
WARNING: This piece was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://baseballnewssource.com/2018/11/10/merian-global-investors-uk-ltd-reduces-stake-in-united-therapeutics-co-uthr/2847008.html.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Story: What does EPS mean?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.